In this week’s insights, we present three recent talking points and findings in the healthcare industry.
FDA approves first generic fluticasone inhaler for asthma treatment
The US Food and Drug Administration (FDA) has approved the first generic version of fluticasone propionate (Flovent HFA) inhalation aerosol.
This approval marks a major step towards improving access to affordable asthma care. The inhaler is approved for patients aged 4 years and older.
Asthma affects over 260 million people globally and remains a frequent cause of hospitalisations and mortality. The introduction of a generic alternative may improve patient adherence to therapy by lowering financial barriers, particularly for long-term use.
Gut-brain interactions may drive age-related memory decline
A preclinical study suggests that age-related cognitive decline may partly arise from changes in the gut microbiome. In a mouse study, age-associated shifts in gut bacteria, such as Parabacteroides goldsteinii, were linked to impaired memory formation through interactions with the vagus nerve.
The researchers identified a pathway in which microbial metabolites promote inflammation, disrupting communication between the gut and the hippocampus, a central brain region involved in memory. Importantly, interventions targeting this pathway were able to restore cognitive function in animal models.
The authors emphasised that these findings, although promising, require validation in humans.
GLP-1 receptor agonists show potential beyond metabolic disease
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used in diabetes and obesity, may also play a role in reducing the risk of substance use disorders (SUDs).
In a large observational study of more than 500,000 US veterans with type 2 diabetes, GLP-1 RA use was associated with a lower risk of developing multiple SUDs, including alcohol, opioid, cannabis, cocaine and nicotine use disorders.
Over a 3-year follow-up, GLP-1 RAs were also linked to fewer hospitalisations, emergency visits and deaths among patients with existing SUDs. These findings suggest that GLP-1 therapies may influence reward pathways and behavioural regulation.
For more industry insights visit elion.nz/insights/
Want to get in touch? Contact us today at https://elion.nz/get-in-touch/
